Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 20/20 | 1.00 |
| ▸ | LOX | P28300 | 2/20 | 1.00 |
| ▸ | LOXL3 | P58215 | 2/20 | 1.00 |
| ▸ | LOXL1 | Q08397 | 2/20 | 1.00 |
| ▸ | LOXL4 | Q96JB6 | 2/20 | 1.00 |
| ▸ | DAO | P14920 | 2/20 | 0.80 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19211740 | 1.00 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| Hydrochloric Acid SCHEMBL19211738 | 1.00 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| SCHEMBL20699505 | 0.99 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| SCHEMBL19254640 | 0.99 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| Hydrochloric Acid SCHEMBL19211695 | 0.94 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| Hydrochloric Acid SCHEMBL19211768 | 0.94 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| Hydrochloric Acid SCHEMBL19211739 | 0.93 | LOXL2 (0.87) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| Hydrochloric Acid SCHEMBL20699556 | 0.93 | LOXL2 (0.87) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| SCHEMBL20699615 | 0.93 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 | |
| SCHEMBL19255140 | 0.93 | LOXL2 (1.00) | LOXL2LOXLOXL3LOXL1LOXL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521358-B2 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent | RAQUALIA PHARMA INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20240216403-A1 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | BIOPHARMA CREDIT PLC (GB) | 2024-07-04 | — | — | US | disclosed |
| WO-2024141952-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | NOVOCURE GMBH (CH) | 2024-07-04 | — | — | WO | disclosed |
| US-20230301950-A1 | METHOD FOR SELECTING CANCER PATIENTS FOR WHOM COMBINATION THERAPY WITH RETINOID AND CANCER THERAPEUTIC AGENT IS EFFECTIVE, AND COMBINATION MEDICAMENT WITH RETINOID AND CANCER THERAPEUTIC AGENT | RAQUALIA PHARMA INC. (JP) | 2023-09-28 | — | — | US | disclosed |
| EP-4173639-A1 | METHOD FOR SELECTING CANCER PATIENT FOR WHICH COMBINATION THERAPY OF RETINOID AND CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINED DRUG OF RETINOID AND CANCER TREATMENT AGENT | RaQualia Pharma Inc. (JP) | 2023-05-03 | — | — | EP | disclosed |
| CN-115997122-A | Method for selecting cancer patients for whom combination therapy of retinoid with cancer therapeutic agent is effective, and combination drug of retinoid with cancer therapeutic agent | 拉夸里亚创药株式会社 | 2023-04-21 | — | — | CN | disclosed |